Amgen launches AMGEVITATM (biosimilar adalimumab) in markets across Europe
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
- Details
- Category: Novartis
Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx® (secukinumab) in patients with psoriatic arthritis (PsA)[1] and ankylosing spondylitis (AS)[2] respectively.
Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world.
Abbott names Robert B. Ford president, chief operating officer
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott's largest business.
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
- Details
- Category: Novartis
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab).
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab),
Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)
- Details
- Category: Merck Group
Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, Germany.
More Pharma News ...
- Pfizer announces Executive Leadership Team
- Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges
- Pfizer to award more than $3 million in grants to further breast cancer research
- Sanofi completes divestiture of Zentiva to Advent
- Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
- Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
- Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC